Tuberculosis in Kidney Transplant Candidates and Recipients

Overview

Journal World J Transplant

Publisher Baishideng Publishing Group

Specialty General Surgery

Date 2024 Sep 19

PMID 39295970

Authors

Pallavi Prasad

Sourabh Sharma

Subashri Mohanasundaram

Anupam Agarwal

Himanshu Verma

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) is the leading cause of infectious mortality and morbidity in the world, second only to coronavirus disease 2019. Patients with chronic kidney disease and kidney transplant recipients are at a higher risk of developing TB than the general population. Active TB is difficult to diagnose in this population due to close mimics. All transplant candidates should be screened for latent TB infection and given TB prophylaxis. Patients who develop active TB pre- or post-transplantation should receive multidrug combination therapy of antitubercular therapy for the recommended duration with optimal dose modification as per glomerular filtration rate.

References

Boubaker K, Gargah T, Abderrahim E, Ben Abdallah T, Kheder A . Mycobacterium tuberculosis infection following kidney transplantation. Biomed Res Int. 2013; 2013:347103. PMC: 3816022. DOI: 10.1155/2013/347103. View

Yehia B, Blumberg E . Mycobacterium tuberculosis infection in liver transplantation. Liver Transpl. 2010; 16(10):1129-35. DOI: 10.1002/lt.22133. View

Hall C, Willcox P, Swanepoel C, Kahn D, van Zyl Smit R . Mycobacterial infection in renal transplant recipients. Chest. 1994; 106(2):435-9. DOI: 10.1378/chest.106.2.435. View

Nordgaard-Lassen I, Frederik Dahlerup J, Belard E, Gerstoft J, Kjeldsen J, Kragballe K . Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012; 59(7):C4480. View

Villarino M, Scott N, Weis S, Weiner M, Conde M, Jones B . Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015; 169(3):247-55. PMC: 6624831. DOI: 10.1001/jamapediatrics.2014.3158. View

Shu C, Tsai M, Lin S, Wang J, Yu C, Lee C . Latent Tuberculosis Infection Increases in Kidney Transplantation Recipients Compared With Transplantation Candidates: A Neglected Perspective in Tuberculosis Control. Clin Infect Dis. 2020; 71(4):914-923. PMC: 7428385. DOI: 10.1093/cid/ciz851. View

Cassidy M, van Zyl-Smit R, Pascoe M, Swanepoel C, Jacobson J . Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient. Nephron. 1985; 41(2):207-8. DOI: 10.1159/000183583. View

El-Agroudy A, El-Baz M, Ismail A, Ali-El-Dein B, Shehab El-Dein A, Ghoneim M . Clinical features and course of Kaposi's sarcoma in Egyptian kidney transplant recipients. Am J Transplant. 2003; 3(12):1595-9. DOI: 10.1046/j.1600-6135.2003.00276.x. View

Falzon D, Schunemann H, Harausz E, Gonzalez-Angulo L, Lienhardt C, Jaramillo E . World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017; 49(3). PMC: 5399349. DOI: 10.1183/13993003.02308-2016. View

10.

Bansal S, Ramasubramanian V, Prasad N, Saraf N, Soman R, Makharia G . South Asian Transplant Infectious Disease Guidelines for Solid Organ Transplant Candidates, Recipients, and Donors. Transplantation. 2023; 107(9):1910-1934. DOI: 10.1097/TP.0000000000004521. View

11.

Prasad P, Bagai S, Prasad V, Grover R, Chhabra G, Khullar D . Kidney transplantation in patients on anti-tubercular therapy: A single centre observational study. Transpl Infect Dis. 2024; 26(3):e14242. DOI: 10.1111/tid.14242. View

12.

Basiri A, Moghaddam S, Simforoosh N, Einollahi B, Hosseini M, Foirouzan A . Preliminary report of a nationwide case-control study for identifying risk factors of tuberculosis following renal transplantation. Transplant Proc. 2005; 37(7):3041-4. DOI: 10.1016/j.transproceed.2005.07.041. View

13.

. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.11 Paediatrics (specific problems). Nephrol Dial Transplant. 2002; 17 Suppl 4:55-8. DOI: 10.1093/ndt/17.suppl_4.55. View

14.

Aguado J, Torre-Cisneros J, Fortun J, Benito N, Meije Y, Doblas A . Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis. 2009; 48(9):1276-84. DOI: 10.1086/597590. View

15.

Guirao-Arrabal E, Torre-Cisneros J . Tuberculin skin test, Interferon gamma release assays or just chest x-ray to study latent tuberculosis before solid organ transplantation?. Transpl Infect Dis. 2018; 20(4):e12920. DOI: 10.1111/tid.12920. View

16.

Alemu A, Bitew Z, Diriba G, Seid G, Eshetu K, Chekol M . Tuberculosis incidence in patients with chronic kidney disease: a systematic review and meta-analysis. Int J Infect Dis. 2022; 122:188-201. DOI: 10.1016/j.ijid.2022.05.046. View

17.

Chenhsu R, Loong C, Chou M, Lin M, Yang W . Renal allograft dysfunction associated with rifampin-tacrolimus interaction. Ann Pharmacother. 2000; 34(1):27-31. DOI: 10.1345/aph.19069. View

18.

Yoon H, Jeon Y, Chung H, Shin S, Hwang H, Lee S . Safety and efficacy of a quinolone-based regimen for treatment of tuberculosis in renal transplant recipients. Transplant Proc. 2012; 44(3):730-3. DOI: 10.1016/j.transproceed.2011.12.065. View

19.

Kuypers D, Verleden G, Naesens M, Vanrenterghem Y . Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther. 2005; 78(1):81-8. DOI: 10.1016/j.clpt.2005.03.004. View

20.

Ngo B, Pascoe M, Khan D . Drug interaction between rifampicin and sirolimus in transplant patients. Saudi J Kidney Dis Transpl. 2011; 22(1):112-5. View